Joint FDA/EMEA application reviews, pre-approval inspections encouraged
This article was originally published in The Gold Sheet
Executive Summary
FDA is jointly reviewing some applications with the European Medicines Agency and would like to jointly review more, agency officials on June 2 told the ISPE Washington conference. "Last week I had two teleconferences with EMEA to discuss submissions that have been submitted to both groups," said FDA's Elaine Morefield. "So prior to approval and taking action we're having discussions on trying to get similar agreement so that we're not taking different actions in different countries unless there's some need to." FDA's Rick Friedman encouraged attendees to "please tell us early if you submit a CTD to Europe and the U.S. and it's at the same time ... and you think it would be a nice candidate for a joint pre-approval inspection.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.